CAR-T cell therapy, originally developed for cancer, is showing ever more promise as a treatment for autoimmune diseases.

Many products have claims to to “support” your mitochondria. For healthy adults, these claims remain largely speculative and ...

STARKVILLE, MS, UNITED STATES, March 31, 2026 /EINPresswire.com/ -- Indee Labs, a company pioneering microfluidic ...

The patent relates to potency assay methods for assessing human mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, peripheral blood, a lung, a heart, amniotic fluid, inner organs, ...

Good day, and thank you for standing by. Welcome to the ORIC Enozertinib Program Update Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would ...

Avance Biosciences opened its new Potency and Cell-Based Assay Center of Excellence, a purpose-built facility designed to expand and centralize the company’s capabilities in potency and functional ...

Scientists are turning venom, radioisotopes, engineered proteins, and AI into powerful new tools against cancer. From Amazonian scorpions yielding molecules that kill breast cancer cells as ...

Series creator Derek Kolstad, known for John Wick, confirmed in an interview with Animation Scoop that a second season depends on the success of the first. Kolstad said the creative team approached ...

Created and written by John Wick and Nobody writer Derek Kolstad, Splinter Cell: Deathwatch is the first animated series to spin out of Splinter Cell, the 25-year-old Ubisoft video game franchise, ...

The estimated streaming release date for Netflix’s Splinter Cell: Deathwatch Season 2 is a big talking point among fans. The show is based on Tom Clancy’s Splinter Cell video games by Ubisoft, the ...

Jeremy has more than 2300 published articles on Collider to his name, and has been writing for the site since February 2022. He's an omnivore when it comes to his movie-watching diet, so will gladly ...

At my lab, we focus on making better CAR T cells to be simpler, more potent, and more effective. A core area of our research is developing one-day, nonactivated CAR T cells, which is a significant ...